Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib preserva función pulmonar y actividad antifibrótica en modelos de fibrosis pulmonar

Tuesday, March 10, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the positive effects of Seralutinib in preserving lung function and exhibiting antifibrotic activity in models of pulmonary fibrosis. This suggests potential therapeutic benefits for patients suffering from related conditions. The findings highlight the drug's relevance in treating pulmonary arterial hypertension and pulmonary fibrosis.
Price reaction · baseline $0.5553 (2026-03-09 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close
-8.7%
day 1
-11.7%
day 3 · peak
-21.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows promise in preserving lung function.
  • Demonstrates antifibrotic activity in pulmonary fibrosis models.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib preserva función pulmonar y actividad antifibrótica en modelos de fibrosis pulmonar
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib?

Seralutinib is a drug being studied for its effects on pulmonary conditions.

How does Seralutinib affect lung function?

It has been shown to preserve lung function in models of pulmonary fibrosis.

What is the significance of antifibrotic activity?

Antifibrotic activity helps reduce fibrosis, improving lung health.

In which conditions is Seralutinib being tested?

It is being tested for pulmonary arterial hypertension and pulmonary fibrosis.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib pulmonary fibrosis lung function antifibrotic
Last updated: Mar 10, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →